Published by Josh White on 25th June 2020
(Sharecast News) - Cell-based therapeutics company ReNeuron Group announced on Thursday that it has signed a new research evaluation agreement with a major United States biotechnology company, in connection with the use of its proprietary exosomes for the delivery of novel gene silencing therapeutics.